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volunteers were atopic, as defined by a positive skin prick test to one Interleukin (IL)-5 is a key cytokine in eosinophil differenor more aeroallergen. All were well controlled with short-acting tiation and maturation in the bone marrow as well as in ␤ 2 -agonists, with no use of corticosteroids or other antiinflammatory recruitment and activation at sites of allergic inflammation drugs in the preceding 8 weeks. All volunteers gave a clear history (4) . IL-5 stimulates the expansion and differentiation of eoof asthma, demonstrated airway hyperresponsiveness with a PC 20 to sinophil precursors (5), upregulates expression of its own histamine of 4.0 mg/ml of less and were nonsmokers. The study was specific receptor ␣ chain during human eosinophil developapproved by the ethics committees of the Royal Brompton and Harement (6), primes eosinophils for enhanced chemotaxis (7) field NHS Trust and the London Chest Hospital, and all volunteers and hyperadherence (8), and delays apoptosis (9). Clinical gave informed consent before participation in the study.
Study Design
This was a two-center, double-blind, placebo-controlled, parallel-group (Received in original form August 2, 2002 ; accepted in final form October 16, 2002) study based at the Royal Brompton and London Chest Hospitals. At an initial screening visit, baseline FEV 1 and histamine PC 20 were measured. of mepolizumab and placebo were compared (Mann-Whitney test). A p value of р 0.05 was considered to be significant.
RESULTS
Eleven volunteers were randomized to receive mepolizumab and 13 to receive placebo. All 24 volunteers completed the study without reporting adverse events or asthma exacerbations. Both groups were well matched for baseline values (Table 1) .
Peripheral Blood Eosinophils and Basophils
At 4 weeks after the first dose of mepolizumab, there was a significant decrease in peripheral blood eosinophil counts in the actively treated group when compared with placebo (p ϭ 0.002). This decrease was maintained throughout the dosing period and was still evident at the time of the repeat bronchoscopy and bone marrow aspirate, Week 10 (p ϭ 0.02) (Figure 2 ). There was a median reduction of 100% from baseline of eosinophils in the actively treated group at Weeks 4 and 10 (interquartile then followed 4 and 8 weeks later with histamine PC 20 measurements range, 67-100%; Figures 2 and 3) . A return of blood eosinophil ( Figure 1 ). counts toward baseline was observed at a mean of 9 weeks after the last dose (range 4-20 weeks, data not shown).
Tissue Processing and Immunohistochemistry
Bronchial mucosal biopsies were fixed, and immunohistochemistry was BALF Eosinophils performed as described previously (10). The BALF was processed as Mepolizumab produced a 79% median reduction in BALF eosin- with a high-affinity antibody to detect both intracellular and
Clinical Parameters
released eosinophil major basic protein, there was no significant reduction in staining intensity after mepolizumab treatment, de-FEV 1 was measured according to standard operating procedure on a bellows spirometer (Vitalograph, Bucks, UK). The FEV 1 measured at spite a 55% reduction in intact eosinophils, and no difference Weeks 0 and 10 were used for the before and after comparisons. The when compared with placebo (Table 2 and Figure 4B ). Comhistamine PC 20 was measured as described previously (18), and the pared with placebo, there were no significant changes in airway before and after measurements were taken from the screening visit and basophils, neutrophils, macrophages, mast cells, or CD3ϩ cells at Week 12. PEFR measurements were recorded for the study duration.
after treatment with mepolizumab ( Table 2 ).
The before and after measurements for PEFR are the median values of the morning PEFR for the weeks preceding Weeks 0 and 10, respecBone Marrow Cells tively.
Treatment with mepolizumab induced a significant decrease in

Statistical Analysis
the percentage of eosinophils within the bone marrow when compared with placebo treatment (p ϭ 0.003) with a median
The Wilcoxon signed rank test was used for within group paired comparisons. For between-group comparisons, the delta values of the effect reduction in the actively treated group of 52.0% (interquartile range, 45-76%; Figure 3 and Table 2 ). There was a 26% reduction in the percentage of bone marrow basophils when mepolizumab treatment was compared with placebo (p ϭ 0.09) ( Table 2) .
Clinical Measures of Asthma
Within the mepolizumab-treated group, there was a significant increase in median morning peak flow between the run-in week and the week after the last dose of treatment (p Ͻ 0.05), although the treatment effect was not significant when compared with placebo (peak flow diaries were available from nine subjects in each group; Table 3 ). There were no changes in clinic FEV 1 or airway hyperresponsiveness measured at screening and Week 12 in the mepolizumab-treated group and no differences from placebo (Table 3) .
DISCUSSION
A previous single-dose study of mepolizumab treatment in asthma reported no effect on allergen challenge or baseline airway hyperresponsiveness despite a substantial reduction in blood and sputum eosinophilia at the highest dose used (15) and was interpreted as evidence against the eosinophil hypothesis of asthma. Although the power of the lung function data in this study has been questioned (19) , it did exclude any major effect of mepolizumab on the late asthmatic reaction. We have ex- extent (median 100% from baseline) and BALF eosinophils by a similar magnitude to that seen in sputum (median 79% from baseline). However, mepolizumab only reduced airway tissue and bone marrow eosinophils by 50%. Furthermore, tissue stainSimilarly, a different humanized monoclonal antibody to IL-5 ing with a high-affinity polyclonal antibody to eosinophil major was reported to have no clinical effect in severe asthma (20). In basic protein showed no significant reduction with anti-IL-5 subjects with asthma of similar severity to those studied here, treatment. Thus, despite high dose anti-IL-5 treatment, there we have previously reported that oral corticosteroid therapy were residual airway eosinophils, with evidence of ongoing dereduced mucosal eosinophil infiltration by a median of 81% (21) . granulation in subjects with asthma. We found no significant We interpret our current findings as showing that mepolizumab difference between anti-IL-5 and placebo on PEFR, airway hypdoes not deplete airway eosinophils sufficiently to impact appreerresponsiveness, or FEV 1 . The relatively modest depletion of ciably on the clinical features of asthma. airway eosinophils by mepolizumab and residual evidence of This study was powered to detect changes in inflammatory eosinophil degranulation may explain the minimal clinical effects cells in the bronchial mucosa rather than on clinical outcome of such treatment in subjects with asthma.
measures. Therefore, given the size of this study, it is not possible The significant increase in morning PEFR is interesting and to exclude a differential effect of mepolizumab on subgroups may be indicative of a small effect; however, there is no statistical significance between the groups, and the FEV 1 was unchanged.
of subjects with asthma. Larger studies are required to allow subgroup analysis on the effects of mepolizumab on subjects absence. Obvious candidates are IL-3 and granulocyte monocyte colony stimulating factor, both of which have been shown to with asthma with different levels of airflow obstruction and/or tissue eosinophilia.
be expressed at increased concentrations in asthmatic airways compared with control subjects (23). Third, our own recent obThe different levels of depletion of blood compared with bone marrow and bronchial mucosal eosinophils by anti-IL-5 servations indicate that incubation of blood eosinophils with IL-5 in vitro profoundly downregulated expression of the IL-5 treatment could be explained in several ways. First, the monoclonal antibody may simply not penetrate tissues or act systemireceptor ␣ chain with a corresponding reduction in IL-5 responsiveness and that this effect was long lasting (B. Gregory, manucally to reach bone marrow and bronchial mucosa. Previous data from other monoclonal antibody treatments and pharmacodyscript in preparation). This raises the possibility that bone marrow and tissue eosinophils recently exposed to IL-5 during namic studies of distribution of anti-IL-5 in animal studies make this explanation unlikely (22) . A second possibility is that aldevelopment and mobilization are less dependent on this cytokine for survival. This may explain persistence and activation of though IL-5 is important in eosinophil development, activation, and survival, other cytokines can sustain tissue eosinophilia in its airway eosinophils despite effective depletion of IL-5. Immunofluorescent staining with a polyclonal anti-MBP antibody of bronchial biopsies before and after mepolizumab, demonstrating no significant change in the levels of extracellular MBP after anti-IL-5 treatment, despite a 55% decrease in intact tissue eosinophils. Vandekerckhove J, North J, Rankin SM, Kay AB, Robinson DS.
The inability of mepolizumab to decrease tissue MBP, despite
Interleukin-5 regulates the isoform expression of its own receptor a 55% reduction in eosinophils, can be interpreted in two ways. 
